Pulmatrix
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2003-01-01
- Employees
- 22
- Market Cap
- $7.5M
- Website
- http://www.pulmatrix.com
Clinical Trials
20
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (19 trials with phase data)• Click on a phase to view related trials
Study to Evaluate Itraconazole Administered as Inhaled Dry Powder in Adults With Asthma and ABPA
- First Posted Date
- 2022-12-28
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Pulmatrix Inc.
- Target Recruit Count
- 8
- Registration Number
- NCT05667662
- Locations
- 🇺🇸
University of Alabama Medical Center at Birmingham, Birmingham, Alabama, United States
🇺🇸Medical Research of Arizona, Scottsdale, Arizona, United States
🇺🇸Jonathan Corren, MD, Santa Monica, California, United States
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of PUR3100 in Health Adults
- Conditions
- Healthy
- Interventions
- Other: Matching Placebo for D.H.E 45Other: Matching Placebo for PUR3100
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2022-12-23
- Lead Sponsor
- Pulmatrix Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT05351086
- Locations
- 🇦🇺
Nucleus Network Melbourne, Melbourne, Victoria, Australia
A Phase 1b Study of PUR1800 in Patients With COPD
- Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
- Interventions
- Drug: Placebo ComparatorDrug: PUR1800 250 ugDrug: PUR1800 500 ug
- First Posted Date
- 2021-02-18
- Last Posted Date
- 2022-06-27
- Lead Sponsor
- Pulmatrix Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT04759807
- Locations
- 🇬🇧
Medicines Evaluation Unit Ltd., Manchester, Wythenshawe, United Kingdom
Study in Adult Asthmatic Patients With Allergic Bronchopulmonary Aspergillosis
- Conditions
- Allergic Bronchopulmonary Aspergillosis
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2021-08-27
- Lead Sponsor
- Pulmatrix Inc.
- Target Recruit Count
- 7
- Registration Number
- NCT03960606
- Locations
- 🇺🇸
National Jewish Health, Denver, Colorado, United States
🇺🇸Yale University School of Medicine, New Haven, Connecticut, United States
🇺🇸Integrity Clinical Research Center Inc., Hialeah, Florida, United States
Safety, Tolerability and Pharmacokinetics of PUR1900 (Itraconazole Powder) in Healthy Volunteers and Adults With Asthma
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2018-07-27
- Lead Sponsor
- Pulmatrix Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT03479411
- Locations
- 🇬🇧
Medicines Evaluation Unit, Manchester, United Kingdom
🇬🇧Quotient Sciences, Nottingham, United Kingdom
- Prev
- 1
- 2
- 3
- Next
News
Pulmatrix to Divest Phase 2-Ready Migraine Treatment and iSPERSE Technology Ahead of Cullgen Merger
Pulmatrix plans to divest its clinical assets including PUR3100, a Phase 2-ready inhaled treatment for acute migraine, as part of its upcoming merger with Cullgen expected to close in June 2025.